Avoiding missed diagnoses and misdiagnoses in autoimmune neurology
Phenotype-specific evaluations provide diagnostic confidence
Patients with autoimmune neurological conditions deserve the best chance at an accurate diagnosis. These answers can make a real difference in a patient’s treatment and quality of life.
Traditional, underpowered paraneoplastic evaluations can lead to false-positive results or missed diagnoses. With our autoimmune and paraneoplastic phenotype-specific evaluations, physicians can order with confidence and diagnose with efficiency, putting patients on the right treatment path sooner.
The complete diagnostic picture
As the field of autoimmune neurology evolves, antibodies once dismissed as rare or of unclear significance are now understood to identify treatable disorders—still uncommon, but likely underrecognized. These antibodies are seldom included in non-specific, traditional paraneoplastic evaluations.
Read more
The two most common antibodies, NMDA-R and GAD65, which account for almost half (46.1%) of positive cases of autoimmune/paraneoplastic encephalitis in adults, are available in our phenotype-specific evaluations but are seldom included in the limited, traditional paraneoplastic evaluations offered by other labs. The third most common antibody, LGI1, which represents 20.5% of positive cases, is also not found in most limited traditional paraneoplastic evaluations.1
In addition, some antibodies that were previously thought to aid diagnosis lack clinical relevance, which can lead to false-positive results and inappropriate treatment. For example, the voltage-gated potassium channel (VGKC) complex antibodies, found in some limited paraneoplastic evaluations, have been shown to lack clinical relevance and increase the risk of false-positive results.2
Stay at the forefront
At Mayo Clinic Laboratories, our research, clinical, and lab experts have developed an approach to autoimmune neurology testing that uses clinically relevant evaluations to lead to confident conclusions. Our evaluations make it easy for physicians to order the appropriate evaluation based on clinical presentation and feel confident they are getting a complete picture of their patient’s condition.
Mayo Clinic Laboratories is on the cutting edge of discovering new, clinically relevant antibodies, such as septin-5, septin-7, and PDE10A. Whether they are discovered here or elsewhere, we update our evaluations to ensure every relevant antibody is being evaluated for your patient. With our paraneoplastic phenotype-specific evaluations, you will always be at the cutting edge.
Do more for patients and providers
Paraneoplastic phenotype-specific evaluations ensure only the right test is performed for the patient, when it is needed, avoiding diagnostic delays and the need for redraws. Ruling out autoimmune-related causes of a patient’s condition with one test can also lead to cost savings, which may not be true of traditional, underpowered paraneoplastic evaluations.
Read more
If the right antibody is not identified up front, additional tests may need to be ordered, potentially subjecting patients to another draw and unnecessarily delaying treatment. If a traditional limited paraneoplastic evaluations is ordered first and the result is negative, the patient’s diagnostic journey continues. Additional inconclusive tests may add cost and cause more patient distress.
Our approach provides peace of mind, knowing every path has been considered to reach the right diagnosis in the most efficient manner.
Autoimmune testing education
Explore the advantages of our autoimmune neurology testing.
Learn more about how our testing can make a difference for your patients. Schedule a time to discuss with one of our clinical specialists.
The latest
In this presentation, Eoin Flanagan, M.B., B.Ch., a leading specialist in neuroimmunology at Mayo Clinic, provides a clear and clinically focused overview of autoimmune conditions that affect the developing nervous system.
In this test-specific episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic, and Bjorn Oskarsson, M.D., a neurologist at Mayo Clinic’s Florida campus, discuss how the neurofilament light chain test available through Mayo Clinic Laboratories helps physicians diagnose neurological disease and assess neuronal damage.
In this month's "Hot Topic," Eoin Flanagan, M.B., B. Ch., discusses the important issue of autoimmune encephalitis misdiagnosis and identifies red flags that be useful in clinical practice to suggest alternative diagnoses and highlight antibodies that sometimes cause confusion.
Andrew McKeon, M.B., B.Ch., M.D., explains how Mayo Clinic Laboratories' expanded movement disorders panel better identifies autoimmune conditions to guide appropriate treatment.
PACEIn this month’s “Virtual Lecture” Eoin Flanagan, M.D., B.Ch., reviews how to diagnose autoimmune encephalitis, what to watch that may suggest a different diagnosis, discuss neural autoantibodies interpretation and putting test results into clinical context.
Education on this topic decreases misdiagnosis and the possibility of misinterpreting the comments provided by the reporting laboratories.
Ed Garber spent months in physical and neurological decline while a cohort of care providers and specialists searched for the root cause of his symptoms. That search for answers ended after testing by Mayo Clinic Laboratories gave them the confirmatory diagnosis they needed.
Andrew McKeon, M.B., B.Ch., M.D., explains how Mayo Clinic Laboratories' pediatric autoimmune/CNS testing can better guide the treatment of autoimmune neurological diseases in children. The tailored evaluation covers only biomarkers relevant to pediatric presentations of the diseases.
Divyanshu (Div) Dubey, M.B.B.S., describes Mayo Clinic Laboratories' new diagnostic test for CIDP, or chronic inflammatory demyelinating polyneuropathy. The new test detects two antibodies — NF155 and CNTN1 — to enhance diagnosis and guide treatment decisions. Often misdiagnosed, CIDP is treatable if detected early.
Alicia Algeciras, Ph.D., describes Mayo Clinic Laboratories’ new blood test to detect NFLC, or neurofilament light chain protein. NFLC is a biomarker for several neurodegenerative conditions. The new assay can determine if a patient’s cognitive decline is due to a neurodegenerative condition or some other, reversible condition — while avoiding the need for more-invasive testing of cerebrospinal fluid.
Mayo Clinic Laboratories is leading an evolution in autoimmune neurology diagnosis. To better reflect this testing evolution, and to reduce confusion and improve utilization for our clients, effective April 28, we are renaming our phenotype-specific evaluations.
Andrew McKeon, M.B., B.Ch., M.D., an expert in neuroimmunology, joins the "Answers From the Lab" podcast for a conversation with Bobbi Pritt, M.D. In this episode, Dr. McKeon and Dr. Pritt discuss how Mayo Clinic is pioneering advancements in the field of autoimmune neurology, how these discoveries were made, and why they are important to both patients and physicians.
The considerations physicians must weigh when evaluating suspected neuropathy patients with special emphasis put on small-fiber neuropathy and the most appropriate laboratory testing related to that phenotype.
Resources
References
- Kunchok A, McKeon A, Zekeridou A, et al. Autoimmune/paraneoplastic encephalitis antibody biomarkers: frequency, age, and sex associations. Mayo Clin Proc. March 2022;97(3):547-559. https://doi.org/10.1016/j.mayocp.2021.07.023
- Lang B, Makuch M, Moloney T, et al. Intracellular and non-neuronal targets of voltage-gated potassium channel complex antibodies. J Neurol Neurosurg Psychiatry. 2017 Apr;88(4):353-361. doi:10.1136/jnnp-2016-314758. Epub 2017 Jan 23.